A stable, orally active, non-prostanoid prostacyclin I2 (PGI2) mimetic and prostacyclin agonist with inhibitory activity against thromboxane A2 synthase.

MAP4343 is the 3-methylether derivative of Pregnenolone. MAP4343 binds in vitro to microtubule-associated protein 2 (MAP2), stimulates the polymerization of tubulin, enhances the extension of neurites and protects neurons against neurotoxic agents.

A fourth-generation synthetic fluoroquinolone, broad-spectrum antibacterial agent that is active against both Gram-positive and Gram-negative bacteria.

FT-671 is a novel potent, specific, non-covalent USP7 inhibitor with Kd of 65 nM (USP7 catalytic domain).

ALE-0540 is a nerve growth factor (NGF) antagonist that inhibits the binding of NGF to TrkA or both p75 and TrkA with IC50 of 5.88 and 3.72 uM, respectively.

(E)-Flupentixol is a non-neuroleptic isomer of (Z)-flupenthixol.

PF-06279794, also known as PF-794, is a potent, selective and ATP-competitive TNIK inhibitor.

JTE 013 is a potent and selective S1P2 antagonist with IC50 of 17.6 nM.

ML-261 is a thienopyrrole-5-carboxamide that inhibits lipid droplet formation.

cis-ISRIB is a weak inhibitor of PERK signaling compared to trans-ISRIB , potently reverses the effects of eIF2α phosphorylation with IC50 of 600 nM.ISRIB reduces the viability of cells subjected to PERK-activation by chronic endoplasmic reticulum stress, displays significant enhancement in spatial and fear-associated learning.ISRIB is a potent inhibitor of the integrated stress response (ISR)integrated stress response (ISR).

SF 2312 is a highly potent, low-nanomolar inhibitor of Enolase with IC50 of 37.9 nM and 42.5 nM for recombinant hENO1 and hENO2 respectively.

SSR-180,575 is a drug which acts as a selective agonist at the peripheral benzodiazepine receptor, also known as the mitochondrial 18 kDa translocator protein or TSPO. It has been shown to have neuroprotective and cardioprotective effects and to stimulate steroidogenesis of pregnenolone in the brain, which may be linked to its neuroprotective action.

A potent, selective ligand for the mitochondrial translocator protein 18kDa (TSPO/PBR).

G6PD activator AG1 (AG1) is a specific, small molecule that increases the activity of the wild-type, Canton mutant (R459L, EC50=3 uM) and several other common G6PD mutants; displays no effect on the dimerization or activity of several other NAD- or NADP+-dependent dimeric or tetrameric enzymes, including 6PGD, GAPDH, ALDH2, and ALDH3A1; attenuates ROS-induced pericardial edema in a G6PD-dependent manner in zebrafish, reduces hemolysis of human erythrocytes

L-Hexanoylcarnitine is an acylcarnitine and is found to be associated with celiac disease.

A peptide corresponding partly to the amino terminus of the Aα chain and Bβ chain of fibrin.

Dnp-PLALWAR is a fluorogenic substrate for matrix metalloproteinase-1 (MMP-1) and MMP-8.

GAPDS is a small molecule that targets the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

Talazoparib, also known as BMN-673 and MDV-3800, is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity (PARP1 IC50 = 0.57 nmol/L). Talazoparib acts as an inhibitor of poly ADP ribose polymerase(PARP) which aids in single strand DNA repair. Cells that have BRCA1/2 mutations are susceptible to the cytotoxic effects of PARP inhibitors because of an accumulation of DNA damage. Talazoparib is theorized to have a higher potency than olaparib due to the additional mechanism of action called PARP trapping. PARP trapping is the mechanism of action where the PARP molecule is trapped on the DNA, which interferes with the cells ability to replicate. Talazoparib is found to be ~100 fold more efficient in PARP trapping than olaparib.

DHAPC is a phospholipid that is very sensitive to oxidation.

Bicyclopyrone is an inhibitor of 4-hydroxyphenylpyruvate dioxygenase (Hpd).

aTAG 2139 (CFT-2139) is an aTAG-based MTH1 fusion protein degrader with a DC50 value of 1.1 nM. aTAG 2139 has a Ki value of 2.1 nM for MTH1.

aTAG 4531 (CFT-4531) is a potent, selective, and onmechanism tool degrader of MTH1 with DC50 value of 0.28 nM and Ki value of 1.8 nM. degradation activity is due to the intricate formation of the ternary complex between the MTH1 aTAG, CRBN E3 ligase, and aTAG tool degrader .

Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy.

CDDD11-8 is a potent CDK9 inhibitor co-targeting FLT3-ITD with Ki values of 8 and 13 nM, respectively.CDDD11-8 displays excellent kinome selectivity in a panel of 369 human kinases.CDDD11-8 displays antiproliferative activity against leukemia cell lines, and particularly potent effects against MV4-11 and MOLM-13 cells, which are known to harbor the FLT3-ITD mutation and mixed lineage leukemia (MLL) fusion proteins.CDDD11-8 causes a robust tumor growth inhibition by oral administration in animal xenografts, induces tumor regression at dose of 125 mg/kg.

IL-17 modulator 3 is an IL-17 modulator (US20200247785A1). IL-17 modulator 3 can be used for the research of inflammation, cancer and autoimmune diseases.

BAY2666605 is a potent, small molecule PDE3A-SLFN12 complex inducer with EC50 of 7 nM.BAY2666605 triggers the formation of a complex of two proteins called SLFN12 and PDE3A. This complex drive cancer cells into cell death by a mechanism called apoptosis.

CFT-8634 (CFT8634) is a potent, selective, orally bioavailable BRD9 BiDAC degrader with DC50 of 3 nM, high selectivity over BRD4 abd BRD7.Unlike BRD9 inhibition, BRD9 degradation is efficacious in preclinical models of synovial sarcoma and CFT8634 is ongoing for the treatment of SMARCB1-perturbed cancers.

Novel selective inhibitor of RARγ

Epothilone B is a Taxol-like microtubule-stabilizing agent with EC0.01 of 1.8 μM.